Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 12/20 | 0.52 |
| ▸ | SLC2A3 | P11169 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27248739 | 0.92 | SLC2A1 (0.49) | MAPTSLC2A1SLC2A3SYK | |
| SCHEMBL31173657 | 0.87 | SLC2A1 (0.50) | SLC2A1SLC2A3MEN1KMT2A | |
| SCHEMBL27249099 | 0.87 | SLC2A1 (0.50) | SLC2A1SLC2A3MEN1KMT2A | |
| SCHEMBL31173666 | 0.86 | ROCK2 (0.49) | SLC2A1SLC2A3 | |
| SCHEMBL27248574 | 0.86 | ROCK2 (0.49) | SLC2A1SLC2A3 | |
| SCHEMBL27249085 | 0.85 | LMNA (0.52) | MAPTSLC2A1SLC2A3MEN1KMT2A | |
| SCHEMBL27248815 | 0.85 | SLC2A1 (0.50) | SLC2A1SLC2A3 | |
| SCHEMBL31173524 | 0.85 | MEN1 (0.50) | SLC2A1SLC2A3MEN1KMT2ASYK | |
| SCHEMBL27248507 | 0.85 | MEN1 (0.50) | SLC2A1SLC2A3MEN1KMT2ASYK | |
| SCHEMBL27248607 | 0.85 | HDAC3 (0.53) | MAPTSLC2A1SLC2A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAPT 1835/4885SLC2A1 1/4885SLC2A3 4/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | MAPT 1835/4885SLC2A1 1/4885SLC2A3 4/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | MAPT 1717/4885SLC2A1 2/4885SLC2A3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.